Researchers have identified a compound that blocks the spread of pancreatic and other cancers in various animal models. When cancer spreads from one part of the body to another in a process called metastasis, it can eventually grow beyond the reach of effective therapies. Now, there is a new plan of attack against this deadly process, thanks to scientists at the National Institutes of Health, Northwestern University and their collaborative research partners.
The team collaborated to identify a compound, which they named metarrestin, that stopped tumor metastasis in multiple animal models. Mice treated with metarrestin also had fewer tumors and lived longer than mice that did not receive treatment. These results were published May 16, 2018 in Science Translational Medicine.
“Many drugs are aimed at stopping cancer growth and killing cancer cells,” said co-author Juan Marugan, Ph.D., group leader of the NIH’s National Center for Advancing Translational Sciences (NCATS) Chemical Genomics Center. “However, there is no single approved drug specifically aimed at treating metastasis. Our results show metarrestin is a very promising agent that we should continue to investigate against metastasis.”
In patients, metarrestin potentially could be effective as a therapy after cancer surgery. Because advanced cancers are difficult to completely remove with surgery, doctors typically give chemotherapy to try to kill undetected cancer cells left behind and prevent the cancer from coming back. Metarrestin could be added to such standard drug therapy.
Metarrestin breaks down an incompletely understood component of cancer cells called the perinucleolar compartment (PNC). PNCs are found only in cancer cells, and in a higher number of cells in advanced cancer, when it has spread to other sites in the body.
Co-author Sui Huang, M.D., Ph.D., and her colleagues at Northwestern University Feinberg School of Medicine, Chicago, showed early on that the more cancer cells with PNCs in a tumor, the more likely it would spread.
Her findings suggested that reducing PNCs might translate to less cancer progression and possibly better outcomes in patients.
To test these ideas, Huang approached Marugan to tap into NCATS’ expertise in screening, chemistry, compound development and testing to evaluate more than 140,000 compounds for their potential effectiveness in eliminating PNCs in cells in advanced cancer.
While nearly 100 compounds initially showed some activity, the investigators identified one compound that could effectively break down PNCs in advanced prostate cancer cells. With the help of researchers at the University of Kansas, Lawrence, they modified the compound to make it work better as a potential drug and evaluated the effects of the molecule in different assays, or tests, in the laboratory. They found that metarrestin could block the way prostate and pancreatic cancer cells spread.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Cedars-Sinai Researchers Develop Drug to Combat Pancreatic Cancer
- HOT SPOTS---Biotech Hot Spots Spread Across Map of Los Angeles
- UCLA Stakes Claim on Inaugural Innovation Day
- Kite Pharma Signs New License with NIH
- Unlikely Entrepreneur---Engineered for Success
- Scientists Explore Ketamine as Tool to Fight Depression
- Abgenix Takeover Gives Amgen Grasp of the Humanized Mouse
- NantWorks Acquires Precision Biologics